Programs

Primary Indication

Preclin

Phase 1

Phase 2

Phase 3

VLS-01
DMT

Treatment Resistant Depression

Phase 2

Phase 2

EMP-01
R-MDMA

Social Anxiety Disorder

Phase 1

Phase 1

IBX-210
Ibogaine

Opioid Use Disorder

Phase 1

Phase 1

Novel 5-HT2A Receptor Agonists

Undisclosed

Preclin

Preclin

STRATEGIC INVESTMENTS

BPL-0031
5-MeO-DMT

Treatment Resistant Depression

Phase 2

Phase 2

ELE-1011
Psilocin

Major Depressive Disorder

Phase 2

Phase 2

RL-0072
Pro-cognitive neuromodulator

Cognitive Impairment Associated with Schizophrenia

Phase 2

Phase 2

Abbreviations: DMT = N,N-Dimethyltryptamine; R-MDMA = R enantiomer of 3,4-Methyl​enedioxy​methamphetamine; 5-MeO-DMT = 5-methoxy-N,N dimethyltryptamine
1 Strategic Investment in Beckley Psytech
2 Majority ownership stake in Recognify Life Sciences

JOIN OUR MAILING LIST

Sign up to receive the latest news on atai.

Email
submit